Oscar Health

OSCR · NYSE

$33.66+$1.12 (+3.44%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $32.54

OSCR analyst rating

HoldConsensus of 11 analysts over the last 12 months. 27% rate it a buy.

Strong buy0
Buy3
Hold7
Underperform1
Sell0

12-month price target · 15 analysts

Average $34.19 (+1.6% upside)

Low: $8.08
Now: $33.66
High: $51.45

Upgrades and downgrades

The latest rating actions, newest first

OSCR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 12, 2026	Maintains	Neutral	$26.00 → $36.00	60%
Raymond James	Sep 18, 2026	Maintains	Outperform	$34.00 → $42.00	65%
B of A Securities	Sep 17, 2026	Maintains	Underperform	$28.00 → $30.00	42%
Stephens & Co.	Sep 17, 2026	Maintains	Equal-Weight	$34.00	71%
Barclays	Sep 17, 2026	Maintains	Overweight	$39.00 → $49.00	59%
Baird	Sep 17, 2026	Maintains	Neutral	$27.00 → $33.00	34%
Wells Fargo	Aug 13, 2026	Maintains	Equal-Weight	$20.00 → $27.00	59%
UBS	Aug 7, 2026	Maintains	Neutral	$20.00 → $26.00	60%
Barclays	Aug 7, 2026	Maintains	Overweight	$35.00 → $39.00	59%
Barclays	Jun 10, 2026	Upgrade	Equal-Weight → Overweight	$30.00 → $35.00	59%

The case for and against

Updated Feb 2, 2026

Bull case

Oscar Health Inc. reported a significant year-over-year revenue growth of 29.0% in 2Q25, reaching $2.86 billion, driven by an increase in retention, market open enrollment growth, and new member additions. The company's medical loss ratio (MLR) improved to 91.1%, well below consensus expectations, reflecting effective management of costs despite a rise in marketwide morbidity. Furthermore, projections indicate substantial growth in enrollment weighted direct policy premiums per member per month (PMPM), anticipated to rise by 28.5% in CY26 and 16.9% in CY27, underscoring a strong growth trajectory for the company.

Bear case

Oscar Health Inc faces significant challenges that could negatively impact its stock performance. The company anticipates a decline in Silver plan enrollment, alongside a projected drop of 20% to 30% in individual ACA Marketplace enrollment due to the potential expiration of E-APTCs by the end of CY25, risking a loss of approximately 6.1 million members year-over-year. Additionally, despite achieving some cost efficiencies with a reduced SG&A ratio, the expected attrition of healthier members and increased adoption of lower-cost Bronze plans may hinder overall revenue growth and profitability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.